{
    "nct_id": "NCT02891603",
    "official_title": "A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression",
    "inclusion_criteria": "* Must have an available 8/8 HLA-A, -B, -C, and -DRB1 matched-related or unrelated donor allogeneic hematopoietic peripheral blood stem cell graft.\n* Signed informed consent.\n* Acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative neoplasms, Hodgkin lymphoma, or non-Hodgkin lymphoma requiring a matched allogeneic hematopoietic stem cell transplantation (HSCT). Acute Leukemia (AML or ALL) must be in complete remission defined as: <5% marrow blasts with no morphologic evidence of leukemia, no peripheral blasts, marrow >20% cellular, and peripheral absolute neutrophil count >1000/uL (platelet recovery is not required). Myelodysplasia (MDS) and chronic myeloid leukemia (CML): Must have <5% marrow blasts. Myeloproliferative neoplasms (MPN): Must have <5% peripheral / marrow blasts. Note: Prior use of a JAK2 inhibitor is allowed up to 4 weeks before day 0 of alloHCT. Hodgkin and non-Hodgkin lymphoma: Must have chemosensitive disease.\n* Adequate vital organ function.\n* Performance status: Karnofsky Performance Status Score â‰¥ 80%.\n\nDonor Eligibility:\n\n* Eligible donors will include healthy sibling, relative or unrelated donors that are matched with the patient at HLA-A, B, C, and DRB1 by high resolution typing as defined by the Collaborative Trials Network.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active infection not controlled with appropriate antimicrobial therapy.\n* History of HIV, hepatitis B, or active hepatitis C infection.\n* Anti-thymocyte globulin, alemtuzumab, bortezomib, or post-transplant cyclophosphamide as part of GVHD prophylaxis.\n* Sorror's co-morbidity factors with total score >4.\n* Any patient anticipating or scheduled to receive a tyrosine kinase inhibitor, FLT3 inhibitor, or JAK2 inhibitor (outside of this study) post-HCT.\n* QTc>450ms per Fridericia's correction.\n* Thrombin time (TT), prothrombin time (PT), or partial thromboplastin time (PTT) >2x upper limit of normal (ULN).\n* Grade 3 or higher recent (within the past 6 months) or ongoing non-QTc cardiac adverse events/comorbidities.\n* Grade 3 or higher recent or ongoing cardiac dysrhythmias, family history of long QT.\n\nsyndrome, or serum potassium <3.0 mEq/L that is persistent and refractory to correction.\n\n* Grade 3 or higher recent or ongoing bleeding events.\n* Symptomatic or uncontrolled cardiovascular disease, myocardial infarction or severe/unstable angina within the past 6 months, or New York Heart Association (NYHA) Class III or IV congestive heart failure.",
    "miscellaneous_criteria": ""
}